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1. Introduction 
Prostate cancer (PC) is the most common male malignancy in Western countries and the 
second most common urological malignancy (Knudsen & Vasioukhin, 2010). In 2008 the 
estimated new cases for PC in the European Union were 382.000 (Ferlay et al. 2010). The 
possibility of early detection is attractive to clinicians and potential patients in spite of the 
fact that until recently concrete evidence that screening would influence PC mortality was 
lacking (Schröder, 2010). There are many risk factors for PC occurrence. The family 
history, genetic and environmental factors and their interaction can contribute to develop 
PC (Colloca & Venturino, 2011). Other risk factors are age, ethnic-racial-geographic 
factors, named constitutional factors, though it is not possible to know what percentage of 
these neoplasms are a result of these risk factors (Ferris-i-Tortajada et al. 2011). The 
polymorphisms in genes associated with PC probably represent the most part of familial 
PC burden. The recent advances in genomic research have made it possible to identify 
several new genomic based biomarkers for PC. These markers are easy to measure and 
stable over time but only one biomarker, prostate specific antigen (PSA), is used in the 
clinical today (Aly et al. 2011). The PSA screening allows to detect PC years before the 
emergence of clinically evident disease, which usually represents locally advanced or 
metastatic cancer (Gjertson & Albertsen, 2011). Treatment options for advanced PC – 
including hormone ablation therapy, radiation and surgery – do not offer cure but delay 
the inevitable recurrence of the lethal hormone-refractory disease. Chemotherapy using 
available anticancer drugs, with the exception of the taxane drug docetaxel, for late stage 
PC does not offer any survival benefit. All of these treatments are costly and have 
significant side effects including impotence and incontinence, which negatively affect the 
quality of life of the patients. Prevention is an important strategy for limiting PC 
morbidity and mortality. Pharmacological and dietary interventions have potentials 
functions in reduction of incident cases and in inhibition of disease progression and 
recurrence (Silberstein & Parsons, 2010). 5-alpha reductase inhibitors remain the 
predominant therapy to reduce the future risk of a PC diagnosis. Dutasteride and 
finasteride are currently the only proven agents for PC risk reduction (Strope & Andriole, 
2010). Among the potential dietary intervention efforts to use of the micro-nutrient 
selenium (Se) in PC clinical trials is emerging as an important highlight and the outcomes 
indicate that Se is a promising treatment. Furthermore, Se inhibits PC through multiple 
mechanisms, and it is beneficial in controlling the development of this disease (Abdulah 
www.intechopen.com
 
Prostate Cancer – Original Scientific Reports and Case Studies 
 
154 
et al. 2011). Se is an essential trace element for humans, animals and some bacteria and it 
is important for many cellular processes, cardiovascular disease, central nervous system 
pathologies and may prevent cancer (Dennert et al. 2011). The evidence that Se is a cancer 
preventive agent includes that from geographic, animal, prospective and intervention 
studies (Tabassum et al. 2010, Schmid et al. 2011).  
Furthermore, literature reports have consistently shown that the different effects of different 
chemical forms and dose of Se (Algotar et al. 2011) on signaling and expression of 
transcripts in PC cells might have important implications in the outcome of ongoing PC 
prevention clinical trials. These include the forms of Se present in the diet and in the body, 
their functions and mechanisms of action, and methods employed in assessing an 
individual’s Se nutritional status – both in general and in epidemiological studies into the 
risk of cancer in relation to diet, as well as in connection with long-term trials for 
investigating the disease-preventive potential of selenium supplementation. Several 
mechanisms have been suggested to mediate the anticancer effects of Se. The major ones are 
reduction of DNA damage; oxidative stress; inflammation; induction of phase II conjugating 
enzymes that detoxify carcinogens; enhancement of immune response; incorporation into 
selenoproteins; alteration in DNA methylation status of tumor suppressor genes; inhibition 
of cell cycle and angiogenesis and induction of apoptosis. The specific mechanisms for PC 
are the inhibition of androgen receptor (AR) signaling, reduction in the mRNA, and protein 
levels of the AR, recruitment of corepressors to the AR elements in the promoters of 
androgen responsive genes, inhibition of signaling pathways like NF-kB, IL-6, Stat3, and 
induction of apoptosis (Nadiminty & Gao, 2008) (Figure 1).    
 
 
Fig. 1. Schematic representation of cellular processes targeted by Se and some specific 
molecular targets in each pathway. Figure from Nadiminty & Gao, 2008 with permission 
from John Wiley and Sons. 
The rapid advance in the knowledge of different selenoproteins and their biological 
functions has opened up new possibilities to increase our understanding of the biological 
effects of Se supplementation (Rebsch et al. 2006). Selenoprotein deficiency leads to the 
accelerated development of lesions associated with PC progression, implicating 
selenoproteins in cancer risk and development and raising the possibility that Se prevents 
cancer by modulating the levels of these selenoproteins. Recently, it has been reported that 
the new discovered selenoprotein, SEP15, which is highly expressed in the prostate, may 
play a role either independently or by modifying the effects of Se in PC survival (Penney et 
al. 2010). Moreover, further research and additional trials of this type are needed to define 
the benefits and risks of different types and doses of Se supplements that in the future may 
be implemented for public health reasons. Another necessary focus for future research is a 
better understanding of the mechanisms by which Se interferes with the carcinogenic 
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processes. The direction of future studies lies in clarifying the effects of these products and 
exploring the biological mechanisms responsible for the prevention of prostate cancer 
(Fairweather-Tait et al. 2011).  This chapter includes information on twenty eight general 
chemical structures containing Se that have shown either anticancer, chemopreventive or 
apoptotic activities. Thus, Se derivatives emerge as promising downstream candidates for 
cancer therapy. 
2. Selenoderivatives against prostate cancer 
2.1 Methylseleninic acid, sodium selenite and sodium selenate 
Some studies have shown that the selenium-based compound methylseleninic acid (MSeA, 
Figure 2) can disrupt AR signaling in PC cells by reaction with reduced glutathione within 
the PC cell (Husbeck et al., 2006). On the other hand, it was observed that a combination of 
MSeA with bicalutamide produced a robust downregulation of PSA through the 
identification of hTERT/telomerase as an important AR target. Telomerase activation has 
been reported in >90% of prostate cancer samples, but not in normal or benign prostatic 
hyperplasia tissues. Telomerase activation play an essential role in cell survival and 
oncogenesis, and inhibition of telomerase has been shown to suppress growth and 
tumorigenic potential of PC (S.A. Liu et al., 2010). Other mechanisms have demonstrated 
that the growth inhibitory effect could be attributed to cell cycle modulation and apoptosis 
induction provoked by MSeA by activation the forkhead box O1 (FOXO1) (H.T. Zhang et al., 
2010). This compound has shown efficacy in transgenic adenocarcinoma of mouse prostate 
model (Wang et al., 2009). Too, it has been investigated in mice model treated with this Se 
form and were observed changes in its proteome (Zhang et al., 2011). In addition, MSeA 
exerted a dose-dependent inhibition of DU145 xenograft growth without genotoxic 
properties (Li et al., 2008). Moreover, in advanced and hormone refractory prostate cancer 
the efficacy of MSeA is based on down regulating hypoxia inducible factor 1α (HIF-1α) 
accompanied of a reduction of vascular endothelial growth factor (VEGF) and  glucose 
transporter 1 (GLUT1) (I. Sinha et al., 2011). On the other hand, MSeA inactivated protein 
kinase C (PKC), particularly the promitogenic and prosurvival epsilon isoenzyme, acting 
through a redox modification of vicinal cysteine sulfhydryls in the catalytic domain of 
PKC (Gundimeda et al., 2008). Some metabolites of MSeA such as methylselenol may 
contribute to their anticancer activities. For example, an upregulation of cyclin dependent 
kinase inhibitor (CDKI) proteins p21Cip 1 and/or p27Kip 1 was observed in DU145 
prostate cancer cells (Wang et al., 2010). Too, a novel mechanism of Se action has been 
proposed for methylselenol due to its ability to inhibit histone deacetylase (HDAC) 
(Kassam et al., 2011). Recently, speciation analysis showed that MSeA was completely 
transformed during the incubations while metabolic conversion of the other Se 
compounds was limited (Lunoe et al., 2011). 
Sodium selenite (Figure 2) is another compound that has been studied in relation to PC and 
it may modulate the androgen receptor through the repression of interleukin-6 (IL-6) (Gazi 
et al., 2007). Too, it was observed that selenite decreased HDAC activity and increased levels 
of acetylated lysine 9 on histone H3, but decreased levels of methylated H3-Lys 9 (Xiang et 
al., 2008). Other mechanisms of action have been postulated such as an increase of the 
activity of the tumor suppressor protein (PTEN) and of the thioredoxin reductase (TR) 
(Berggren et al., 2009). Too, selenite is able to induce cell death and apoptosis by production 
of superoxide in mitochondria in LNCaP cells (Xiang et al., 2009). In 2010 was reported that 
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sodium selenite inhibited the lipopolysaccharide (LPS)-induced TLR4-NF-kB signaling in 
PC-3 (Pei et al., 2010). Sodium selenite can act alone or in combination with other treatments 
for PC. So, this compound significantly enhances the effect of radiation on well established 
hormone-independent prostate tumors and does not sensitize the intestinal epithelial cells to 
radiation. These results suggest that may increase the therapeutic index of radiation therapy 
(Tian et al., 2010). In addition, the effectiveness on PC treatment of the association between 
sodium selenite and docetaxel has resulted as a new strategy in PC therapeutic approach 
(Freitas et al., 2011). Too, combination of genistein and selenite has shown synergistic effects 
on apoptosis, cell cycle arrest associated signaling pathways in p53 expression (Zhao et al., 
2009). Actually, other inorganic forms of Se as sodium selenate (Figure 2), where Se is in 
oxidation state + 6, are in Phase I studies and have shown antiangiogenic properties 
(Corcoran et al., 2010). 
 
 
Fig. 2. Methylseleninic acid, sodium selenite and sodium selenate structures. 
2.2 Methylselenocysteine and selenomethionine 
Se may exert its beneficial effects through incorporation into selenoproteins including, 
glutathione peroxidases, selenoprotein P, iodothyronine deiodinases and thioredoxin 
reductases. There are more than 30 selenoproteins that have been identified in humans and 
they are involved in a range of cellular functions including immune function and protection 
against lipid and DNA damage. The cancer preventive mechanisms of action of 
methylselenocysteine (MeSeCys) (Figure 3) in human prostate cells are variable. A 
mechanism of action proposed for MeSeCys is that can alter the expression of several types 
of collagen gene and protein expression and thus may impact on the extracellular matrix 
and alter prostate cell progression and invasion (Hurst et al., 2008). Other authors affirm 
that the effect is due to methylselenol, a metabolite active in a study carried out in the 
transgenic adenocarcinoma mouse prostate model by oral administration of MeSeCys (J. 
Zhang et al., 2010). This hypothesis has been reinforced and completed in 2011 with the 
inclusion of new metabolites, the α-keto acids analogues of MeSeCys (Pinto et al., 2011). 
Related to selenomethionine (SeMet) (Figure 3) one of the mechanism that is gaining interest 
is the HDAC inhibition by metabolites of SeMet accompanied of redox signaling proteins 
modulation (J.I. Lee et al., 2009). Too, in combination with genistein induced growth arrest 
with modulation of expression of matrix metalloproteinase-2 (MMP-2) (Kumi-Diaka et al., 
2010). On the other hand, this compound has been employed in order to reduce the toxic 
effects of di(2-ethylhexyl)phthalate (DEHP), an abundant plasticizer environmental 
contaminant that causes alterations in endocrine and spermatogenic functions mediated by 
induction of reactive oxygen species (ROS) and activation of nuclear p53 and p21 proteins in 
LNCaP cells. The SeMet supplementation reduced ROS production with modulation of 
intracellular redox status that is related to response against testicular toxicity (Erkekoglu 
et al., 2011). If we consider the possibility of combination between SeMet and other 
compound for modulating PC development the results are drug dependent. So, SeMet 
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and alpha-tocopherol do not inhibit prostate carcinogenesis in the testosterone plus 
estradiol treated NBL rat model (Ozten et al., 2010). However, the selected combination of 
silymarin and SeMet significantly reduced two markers of lipid metabolism known 
associated with PC progression (Vidlar et al., 2010). In order to improve the activity and 
safety inorganic and organic hybrid nanoparticles are potentially useful in biomedicine, 
mainly for tumor treatments (Choi et al., 2010). Se nanoparticles are safer compared with 
SeMet isolated and was observed an inhibition of the growth of prostate LNCaP cancer 
cells partially through caspases mediated apoptosis, Akt kinase modulation and by 
disrupting AR (Kong et al., 2011). 
 
 
 
Fig. 3. Methylselenocysteine and selenomethionine structures. 
2.3 Selenocyanate derivatives 
The first selenocyanate described was 1,4-phenylenebis(methylene)selenocyanate (p-XSC) 
(Figure 4). The most recent studies postulate that this compound is capable of altering 
cofilin-2, single-stranded mitochondrial DNA binding protein, chaperonin 10, nucleoside 
diphosphate kinase 6 and chain A Horf 6 human peroxidase enzyme in LNCaP cells and in 
its androgen independent clone (AI) (R. Sinha et al., 2008). Too, this compound can induce 
apoptosis, inhibits AR expression and decreases Akt phosphorylation (Facompre et al., 
2010). Other organic selenocyanates have emerged during the last years. So phenylalkyl 
isoselenocyanates (Figure 4), isosteric selenium analogues of naturally occurring 
phenylalkyl isothiocyanates, have shown a reduction in tumor size associated to apoptosis. 
The structure activity relationship studies concluded that an increase in the alkyl chain 
length is critical for the activity being n = 4, named ISC-4, the optimal (Sharma et al., 2008). 
In 2011, these same authors have reported that ISC-4 activates prostate apoptosis response 
protein 4 (Par-4) (Sharma et al., 2011). As a continuation of the synthesis of novel alkyl 
selenocyanates in 2010 was described the synthesis of substituted naphthalimide based 
organoselenocyanates (Figure 4) with the alkyl chain length n = 5 and investigated their 
systematic toxicity profile in mice by consideration changes in body weight, hepatotoxicity 
and nephrotoxicity resulting less toxic than other selenium forms but retaining the efficacy 
(Roy et al., 2010). Numerous studies have been conducted to elucidate the mechanism 
underlying the antitumor effects associated with cyclooxygenase 2 (COX-2) inhibitors. 
However, this mechanism has not yet been clearly defined. Nonsteroidal anti-
inflammatory drugs (NSAIDs) have been shown to retard the progression of PC in men 
and NSAIDs have been used in clinical trials for prostate cancer. Celecoxib (Celebrex), a 
specific COX-2 inhibitor, reduces prostate tumors in experimental models mainly through 
cell cycle regulation and angiogenesis. However, the growth inhibitory properties of 
Celecoxib may be COX-2 independent. Considering this possible effect a novel strategy 
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has been proposed based on to combine selenium and COX-2 inhibitor. Considering that 
sulfonamide moiety and pyrazole ring are important for the proapoptotic activity of 
Celecoxib against PC, the Selenocoxib-1 (Figure 4) was synthesized. The structural 
modifications introduced were the replacement of the trifluoromethyl group by 
methyleneselenocyanate fragment and the elimination of the methyl group. The study 
carried out against PAIII cells derived from a metastatic prostate tumor that arose 
spontaneously in a Lobund-Wistar (LW) rat. In addition, human metastatic prostate 
cancer cells, PC-3M, were tested for antitumor effect of Selenocoxib-1 in vitro. Selenocoxib-
1 induced apoptosis in a dose-dependent manner in the PAIII cells and resulted more 
effective against PC than Celecoxib (Desai et al., 2010a). Other modulations have been 
introduced maintaining the methyl group in order to obtain Selenocoxib-2 (Figure 4) but it 
has not been studied as antitumoral yet (Desai et al., 2010b). 
 
 
 
 
Fig. 4. Chemical structures for selenocyanate derivatives. 
2.4 Heterocycles containing selenium 
Ebselen (Figure 5) is one of the most relevant heterocyclic compounds derived from 
selenium. Ebselen is a glutathione peroxidase mimetic seleno-organic compound that 
attenuates the H2O2 level. In this process a hydroxylamine spin trap reacts with oxygen-
centered radicals, including superoxide. It was seen that this compound blocked the 
expression of the disintegrin and metalloprotease ADAM9 in LNCaP or C4-2 PC cells 
through inhibition of ROS production (Sung et al., 2006). In other studies Ebselen was used 
as an external agent for reverting biochemical processes such as glycolysis. For example, 
ABC transporters like P-glycoprotein (P-gp/ABCB1), that are membrane proteins 
responsible for the transport of toxic compounds out of non-malignant cells and tumor 
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tissue can be modified in their expression by coincubation with ebselen (Wartenberg et al., 
2010).  Too, it has been used for protecting PC-3 cells against apoptosis induction provoked 
by curcumin, a potent anticancer agent (Hilchie et al., 2010). On the other hand, ebselen has 
been reported as a covalent inactivator of α-methylacyl coenzyme A racemase (AMACR), a 
metabolic enzyme whose overexpression has been shown to be a diagnostic indicator of 
prostatic adenocarcinoma and other solid tumors and has been employed as reference drug 
for screening of approximately 5000 unique compounds as AMACR inhibitors (Wilson et al., 
2011). In structural relation with ebselen is the organoselenium compound 1,2-bis-[1,2-
benzisoselenazolone-3(2H)-ketone]ethane (BBSKE) (Figure 5), which has shown an 
inhibitory effect on the growth of a variety of human cancer cells, provokes S phase arrest 
accompanied by increases in the protein levels of cyclin A, E and p21 and decreases in levels 
of cyclin B1, D1 and Cdk4 (Shi et al., 2003a, 2003b). A recent study carried out in rats affirms 
that the metabolites of BBSKE can act as antitumoral agents (Zhou et al., 2010). Too, in 
association with cisplatin increases the sensitivity of the colon cancer cell line LoVo towards 
cisplatin via regulation of G1 phase and reversal of G2/M phase arrest (Fu et al., 2011). The 
formulation as copolymer micelles allows the accumulation into tumor efficiently due to an 
increase in water solubility (M. Liu et al., 2010). 
D-501036, 2,5-bis(5-hydroxymethyl-2-selenienyl)-3-hydroxymethyl-N-methylpyrrole (Figure 
5), has been identified as a novel antineoplastic agent with a broad spectrum of 
antitumoural activity against several human cancer cells and has an IC50 value in the 
nanomolar range. This compound induces cell death associated with the DNA damage-
mediated induction of ataxia telangiectasia-mutated activation without interfering with 
topoisomerase-I and topoisomerase-II function (Juang et al., 2007). Another mechanism that 
has been proposed for the activity of D-501036 is angiogenesis inhibition. Although anti-
angiogenesis strategies have generated a great deal of enthusiasm for therapeutic 
applications, it is still unknown whether these systems would be feasible for prevention. The 
possibility of interfering very early in tumour progression by modulating the cancer 
angiogenic switch is appealing, though there is increasing evidence for close correlation 
between inflammation, the micro-environment and tumour-associated neo-angiogenesis 
causing the adverse outcomes of prostate cancer (Araldi et al., 2008). 
In 2010, a new series of heterocyclic organoselenium compounds were synthesized and 
evaluated as possible chemopreventive agents in human prostate cancer LNCaP cells. Two 
of this 3-selena-1-dethiacephem derivatives (Figure 5) strongly activated nuclear factor E2-
related factor 2 (Nrf2)/ antioxidant response element (ARE) signaling that regulate 
expression of phase II antioxidant and detoxifying enzymes such as glutathione peroxidase 
(GPX), γ-glutamylcysteine synthetase (γ-GCS), heme oxygenase-1 (HO-1), NADPH quinone 
oxidoreductase (NQO-1), and glutathione S-transferase (GST) expression. These two 
compounds also possessed a potent antioxidant activity. Furthermore, both compounds 
were capable of inhibiting cell growth via cell cycle arrest. Related to structure activity 
relationship the presence of the exo-olefin (carbon–carbon double bond) as well as the 
aliphatic substitution at the imine part is critical for these compounds to activate Nrf2/ARE 
signaling (Terazawa et al., 2010). Other interesting derivatives are 2-substituted 
selenazolidine-4(R)-carboxylic acids (Figure 5). There are numerous studies that concern the 
induction of a protective hepatic enzyme related to gluthathione-S-tranferase and 
gluthathione peroxidase and it seemed of interest to evaluate these compounds in PC cells 
(El-Sayed et al., 2007, Poerschke & Moos 2011). 
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Fig. 5. Chemical structures for heterocycles containing selenium. 
2.5 Selenide and diselenide derivatives 
The selenide function is present in a lot of organoselenium compounds. Many of the above 
described derivatives possess this type of bond (i.e. MeSeCys, SeMet,). One compound does 
not described in the above sections is p-xylylbis(methylselenide) (p-XMS) (Figure 6), a 
organoselenium compound that modifies the growth, secretion of PSA and the intracellular 
redox status and genomic profiles (Pinto et al., 2007). Too, the selenide function is present 
linked to nucleosides. The natural nucleosides may be used as Se-carriers. The synthesis and 
antitumor activity of novel nucleosides derivatized from uridine and thymidine (Figure 6), 
with a selenomethyl group at various positions has been described. In general, the activity 
against PC cells is position-dependent. Compounds with the selenomethyl group in position 
5’ are more active than the corresponding in 2’ or 3’. The probable explanation is that it is 
easier to metabolize the Se-nucleoside containing the primary selenomethyl than the 
secondary selenomethyl, thereby generating more methylselenol (Lin et al., 2009). The 
natural products continue to be a rich source of new promising substances for cancer 
therapy. Sesquiterpene lactones (SQLs) are a class of naturally occurring plant terpenoids of 
Asteraceae family, known for their various biological activities such as cytotoxicity against 
different tumor cell lines. Many authors have linked this activity mainly to the α-methylene-
γ-lactone functionality, which is prone to react with suitable nucleophiles, e.g., sulfhydryl 
groups of cysteine, in a Michael addition mechanism. These reactions are nonspecific, 
leading to the inhibition of a large number of enzymes or factors involved in key biological 
in spite of it is well known, however, that the α-methylene-γ-lactone moiety is not an 
absolute requirement for cytotoxicity. In this context emerge other interesting compounds 
such as the alpha-santonin derivatives (Figure 6) a sesquiterpene lactone isolated from 
Artemisia santonica. The compounds with higher activity showed as common structural 
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feature the presence of an alpha-methylidene-gamma-butyrolactone moiety in their 
structures (Arantes  et al., 2009).   This hypothesis has been corroborated in other tumoral 
cell lines. In addition, the bioactive α-santonin derivatives are selective against cancer cells 
(Arantes et al., 2010). 
It is well established that various human diseases, including PC, are associated with a 
disturbed intracellular redox balance and oxidative stress (OS). Se based agents (Figure 6) 
turn the oxidizing redox environment present in certain cancer cells into a lethal cocktail of 
reactive species that push these cells over a critical redox threshold and ultimately kill them 
through apoptosis. The main advantage is that this kind of toxicity is highly selective: 
normal, healthy cells remain largely unaffected, since changes to their naturally low levels of 
oxidizing species produce little effect though the biochemical pathways triggered by these 
agents need to be studied in more detail such as redox modulator like cysteine-containing 
Bcl proteins, which control apoptosis at an early stage, certain caspases, which execute 
apoptotic mechanisms further downstream, are also redox sensitive (Jamier et al., 2010).  
 
 
Fig. 6. Chemical structures for selenide and diselenide derivatives. 
2.6 Selenium and metal complexes 
Selenium- and sulfur-containing compounds have been widely studied as potential 
antioxidants for the prevention or reduction of oxidative DNA damage and the 
organoselenium compounds are of particular interest because they appear to be more 
bioavailable relative to inorganic Se compounds. The Se and sulfur antioxidant activity has 
been explained using copper-mediated DNA damage studies and UV-vis spectroscopy that 
have allowed identifying a copper coordination through a novel metal bond. For this reason 
has been described the synthesis of relevant copper selone complexes with 
tris(pyrazolyl)methane or tris(pyrazolyl)borate ligands (Figure 7) (Kimani et al., 2010). The 
determination of redox potential for Cu-Selone complexes indicated that Se coordination to 
copper in biological systems may prevent the reduction of Cu2+ by NADH required for the 
catalytic formation of damaging hydroxyl radical. 
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Fig. 7. Chemical structure for Cu-Selone complexes. Reprinted with permission from Kimani 
et al., 2010. Copyright 2010 American Chemical Society. 
2.7 A case study: Novel selenoderivatives as cytotoxic agents and apoptosis inducers 
in prostate cancer cells 
In the last four years, several articles have been published by our research group related to 
the design, synthesis and biological evaluation of novel compounds containing Se as 
cytotoxic agents and apoptosis inducers. In addition, mounting evidence suggests that 
selenium (Se) works by inhibiting important early steps in carcinogenesis in a variety of 
experimental models and the anticancer activity is dependent on the chemical form of 
selenium. Se occurs in both organic and inorganic forms. Based on these findings we 
envisaged a new investigation that involves the synthesis of new compounds that 
incorporate the Se-containing moiety. 
2.7.1 Structures and biological results 
Initially, the rationale behind the design of these compounds was to maintain molecular 
symmetry, a structural property that is frequently present in cytotoxic and pro-apoptotic 
drugs (Sanmartín et al., 2006). The structures synthesised correspond to molecules with a 
central nucleus made up of an alkyl imidothiocarbamate (alkyl isothiourea) or alkyl 
imidoselenocarbamate (alkyl isoselenourea) connected by a carbonyl group on each side 
to two identical lateral aromatic or heteroaromatic rings mono, bi or polycyclics (Figure 
8). The sulfur and selenium substituents were varied (methyl, ethyl, benzyl and isopropyl) 
to determine the effect of the alkyl chain length and the ramifications that this has on the 
activity (Plano et al., 2007, Ibáñez et al., 2011). The best results in PC-3 were obtained for 
the compound with X = Se, Y = C, R = CH3 and R' = 4-CH3. This compound was the most 
potent (IC50 = 1.85 μM) and was 4.5 times more active than standard methylseleninic acid 
(IC50 = 8.38 μM) and 7.3 times more active than etoposide (IC50 = 13.6 μM), an agent used 
in the treatment of PC. In addition, the novel compound was less toxic than the reference 
and apoptotic inducer in MCF-7 and CCRF-CEM. For the heteroaromatic rings thienyl and 
quinolinyl were the most interesting. During the course of our work a great number of 
different structural classes of selenocompounds were reported (Sanmartín et al., 2008). For 
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this reason, and in order to improve the potency of our compounds, we decided to 
introduce some structural modifications. Among these modifications was the preparation 
of new compounds with related structures based on aroyl and heteroaroyl selenylacetic 
acid derivatives (Figure 8). The most promising derivatives against PC-3 cancer cells were 
the corresponding phenyl, 3,5-dimethoxyphenyl and benzyl with TGI values of 6.8, 4.0 
and 2.9 μM (Sanmartín et al., 2009). Too, there is current interest in heterocyclic 
compounds that contain a Se atom in the ring. Bearing this fact in mind, and as a 
continuation of our previous work, we proposed the synthesis 1,2,5-selenadiazolo[3,4-
d]pyridines and 1,2,5-benzoselenadiazolo derivatives (Figure 8). The most promising 
molecule was a pyridine derivative (Plano et al., 2010b). Other explored structures were 
compounds with selenocyanate and diselenide moieties. Moreover, we evaluated their 
antioxidant-prooxidant properties so as their cytotoxic activities against PC-3 resulting 
eighteen of the fifty-nine compounds evaluated more potent than etoposide (Plano et al., 
2010a). Taking into account that oxidation state for Se is related to antitumoral effect we 
have synthesized and evaluated an original series consisting of a small group of 
compounds which possess Se in the +4 states oxidation instead of Se +2 (Figure 8) (Plano 
et al., 2010a). 
 
 
 
 
Fig. 8. Selenoderivatives obtained and evaluated by our research group. 
Considering that Se has been associated with an anticancer effect via the modulation of 
some kinase such as Akt (J.H. Lee et al., 2008) some of these compounds have been studied 
as kinase modulators. Some of them modulate CK1A and GS3Ka expression and a weak 
modification in ErB4, GS3Ka and PKCA was detected (unpublished results). 
The preliminary results from the biological screening of these novel compounds are very 
encouraging and these systems could offer an excellent framework in this field and may 
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ultimately lead to discovery of potent antitumour agent. Thus, the search for new drugs 
with Se continues to be a great challenge in medical science. 
3. Conclusion 
It is clear from the studies discussed above that Se compounds do have effects on growth, 
cell cycle and apoptosis and that such compounds offer great promise as anticancer and 
apoptotic agents in many tumoral processes, mainly for PC. In this chapter we have 
summarized information on more than twenty eight structures that contain Se – most of 
which were published in the last three years – and possess cytotoxic activity against PC. 
This list of compounds and references is by no means exhaustive and merely hints at the 
hundreds of other citations due to the ever increasing amount of work carried out in this 
field. As a result of these studies, Se derivatives are rapidly emerging as valid 
chemotherapeutic agents. However, various organic and inorganic selenium compounds 
used in some studies have produced variable results when they are tested in animal models 
and human subjects and more investigations are urgently needed in order to ascertain the 
safety in their use. We have included some structures that have not yet been evaluated in 
prostate cancer cells because we believe that the study of these compounds would be of 
interest. Although several possible mechanisms have been proposed to explain the 
anticancer and apoptotic properties of selenium compounds, the results described here 
suggest the following preliminary considerations: 
1. The chemical form is a determinant factor for the activity and the metabolism is 
required for anticarcinogenic activity. 
2. The effect of some selenium compounds mainly depends on the dose and the oxidation 
state of selenium. For inorganic selenium compounds the +4 oxidation state gives the 
highest anticarcinogenic properties and for organic selenium compounds the activity is 
mainly observed for the +2 oxidation state. 
3. The existence of diverse responses for the same chemical structure suggests several 
mechanisms of action. For example, sodium selenite induced apoptosis by redox 
processes, decreased HDAC activity, increased of PTEN activity. The expectation of a 
broad therapeutic benefit from agents that target only one member of either pathway may 
be overly simplistic due to the complex interrelated network governing apoptosis. 
4. Experimental evidence shows that molecular symmetry, as a broad concept, could be a 
positive factor for cancer prevention and apoptosis (sodium selenite, methylseleninic 
acid, p-XSC, p-XMS, BBSKE). The importance of molecular symmetry in cytotoxic and 
pro-apoptotic activities was reported by us in 2006. Recently, we described a new series 
of symmetrical organoselenium compounds that are potent as cytotoxic agents in 
prostate cancer cells. 
This class of compound offers a great deal of promise to broaden significantly the horizons 
of modern apoptosis and anticancer drug discovery for the potential treatment of prostate 
cancer. Animal data, epidemiological data, and intervention trials have shown a clear role 
for selenium derivatives in both the prevention of specific cancers and antitumourigenic 
effects in postinitiation phases of cancer through apoptosis induction. Accordingly, in recent 
years there has been substantial interest directed toward the synthesis of selenium-
containing derivatives that could be used as cytotoxic, cancer chemopreventive and 
apoptotic agents. However, a great deal of further research is needed to unravel the precise 
manner in which selenium compounds act.  
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